Although GSK witnessed a sales recovery in Q4, fresh lockdowns meant the top line was still in the red – Consumer Healthcare and Pharmaceuticals were the key drags, though Vaccines posted a strong show. Given the COVID-19-related disruptions, management anticipates a soft H1 21 with normality guided for H2. Ergo, the FY21 EPS is seen mid-to-high single-digit lower (vs. FY20: -4%). The spin-off of Consumer Healthcare remains on track for FY22 but a couple of recent R&D setbacks raise questions o ....
05 Feb 2021
Gloomy outlook for FY21; R&D setbacks worrisome
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Gloomy outlook for FY21; R&D setbacks worrisome
GSK plc (GSK:LON) | 1,709 0 0.0% | Mkt Cap: 70,819m
- Published:
05 Feb 2021 -
Author:
Rishabh Kochar | Amandeep Goyal -
Pages:
5
Although GSK witnessed a sales recovery in Q4, fresh lockdowns meant the top line was still in the red – Consumer Healthcare and Pharmaceuticals were the key drags, though Vaccines posted a strong show. Given the COVID-19-related disruptions, management anticipates a soft H1 21 with normality guided for H2. Ergo, the FY21 EPS is seen mid-to-high single-digit lower (vs. FY20: -4%). The spin-off of Consumer Healthcare remains on track for FY22 but a couple of recent R&D setbacks raise questions o ....